CARLSMED, INC.(CARL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

CARLSMED, INC. (CARL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CARL at 28.6/100 on a 32-signal composite quality model, placing it at rank #2,553 of 2,962 stocks — the bottom half of the AI-ranked universe. CARL scores in the top quartile across revenue growth (89.5). Areas of concern include balance sheet strength (4.5) and free cash flow (8.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CARLSMED, INC. reports quarterly revenue of $18.9M, net income of $-10.5M, an operating margin of -58.3%. Top institutional holders of CARL by reported 13-F value include Jupiter Topco, Parkman Healthcare Partners, BlackRock, based on the most recent SEC filings. CARL trades on the Nasdaq exchange and files with the SEC under CIK 1794546. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CARL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CARLSMED, INC. directly from SEC EDGAR.